Interferon-λ in HCV infection and therapy

Viruses

Volumn 2, Issue 8, 2010, Pages 1589-1602

  Pagliaccetti, Nicole E ^a   Robek, Michael D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IFN ; IL 28; IL 28r ; IL 29; IL28b; Type III interferon

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN 28B; LAMBDA INTERFERON; LAMBDA2 INTERFERON; LAMBDA3 INTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON LAMBDA1; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; FATIGUE; GENE EXPRESSION REGULATION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HERPES SIMPLEX; HUMAN; IMMUNOMODULATION; INFLUENZA A; IRRITABILITY; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; MYALGIA; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; PATHOGENESIS; POXVIRUS INFECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ANALYSIS; THOGOTOVIRUS INFECTION; THROMBOCYTE COUNT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS LOAD; VIRUS RECOMBINANT; WEST NILE FEVER;

HEPATITIS C VIRUS;

EID: 79952172888     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2081589     Document Type: Review

References (73)

1. Kotenko, S.V.; Gallagher, G.; Baurin, V.V.; Lewis-Antes, A.; Shen, M.; Shah, N.K.; Langer, J. A.; Sheikh, F.; Dickensheets, H.; Donnelly, R.P. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4, 69-77.
2. Sheppard, P.; Kindsvogel, W.; Xu, W.; Henderson, K.; Schlutsmeyer, S.; Whitmore, T.E.; Kuestner, R.; Garrigues, U.; Birks, C.; Roraback, J.; Ostrander, C.; Dong, D.; Shin, J.; Presnell, S.; Fox, B.; Haldeman, B.; Cooper, E.; Taft, D.; Gilbert, T.; Grant, F.J.; Tackett, M.; Krivan, W.; McKnight, G.; Clegg, C.; Foster, D.; Klucher, K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4, 63-68.
3. Gad, H.H.; Dellgren, C.; Hamming, O.J.; Vends, S.; Paludan, S.R.; Hartmann, R. Interferonlambda Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family. J. Biol. Chem. 2009, 284, 20869-20875.
4. Kotenko, S.V.; Izotova, L.S.; Mirochnitchenko, O.V.; Esterova, E.; Dickensheets, H.; Donnelly, R.P.; Pestka, S. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL- 10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cellderived inducible factor, IL-TIF) receptor complexes. J. Biol. Chem. 2001, 276, 2725-2732.
5. Kotenko, S.V.; Krause, C.D.; Izotova, L.S.; Pollack, B.P.; Wu, W.; Pestka, S. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 1997, 16, 5894-5903.
6. Wolk, K.; Kunz, S.; Asadullah, K.; Sabat, R. Cutting edge: immune cells as sources and targets of the IL-10 family members? J. Immunol. 2002, 168, 5397-5402.
7. Sommereyns, C.; Paul, S.; Staeheli, P.; Michiels, T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, 4, e1000017.
8. Witte, K.; Gruetz, G.; Volk, H.D.; Looman, A.C.; Asadullah, K.; Sterry, W.; Sabat, R.; Wolk, K. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009, 10, 702-714.
9. Mordstein, M.; Kochs, G.; Dumoutier, L.; Renauld, J.C.; Paludan, S.R.; Klucher, K.; Staeheli, P. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 2008, 4, e1000151.
10. Mordstein, M.; Neugebauer, E.; Ditt, V.; Jessen, B.; Rieger, T.; Falcone, V.; Sorgeloos, F.; Ehl, S.; Mayer, D.; Kochs, G.; Schwemmle, M.; Gunther, S.; Drosten, C.; Michiels, T.; Staeheli, P. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 2010, 84, 5670-5677.
11. Wang, J.; Oberley-Deegan, R.; Wang, S.; Nikrad, M.; Funk, C.J.; Hartshorn, K.L.; Mason, R.J. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda1) in response to influenza A infection. J. Immunol. 2009, 182, 1296-1304.
12. Ank, N.; Iversen, M.B.; Bartholdy, C.; Staeheli, P.; Hartmann, R.; Jensen, U.B.; Dagnaes-Hansen, F.; Thomsen, A.R.; Chen, Z.; Haugen, H.; Klucher, K.; Paludan, S.R. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008, 180, 2474-2485.
13. Iversen, M.B.; Ank, N.; Melchjorsen, J.; Paludan, S.R. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J. Virol. 2010, 84, 4579-4586.
14. Coccia, E.M.; Severa, M.; Giacomini, E.; Monneron, D.; Remoli, M.E.; Julkunen, I.; Cella, M.; Lande, R.; Uze, G. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 2004, 34, 796-805.
15. Osterlund, P.; Veckman, V.; Siren, J.; Klucher, K. M.; Hiscott, J.; Matikainen, S.; Julkunen, I. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virusinfected human myeloid dendritic cells. J. Virol. 2005, 79, 9608-9617.
16. Onoguchi, K.; Yoneyama, M.; Takemura, A.; Akira, S.; Taniguchi, T.; Namiki, H.; Fujita, T. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 2007, 282, 7576-7581.
17. Zhou, L.; Wang, X.; Wang, Y.J.; Zhou, Y.; Hu, S.; Ye, L.; Hou, W.; Li, H.; Ho, W.Z. Activation of toll-like receptor-3 induces interferon-lambda expression in human neuronal cells. Neuroscience 2009, 159, 629-637.
18. Zhang, S.Y.; Jouanguy, E.; Sancho-Shimizu, V.; von Bernuth, H.; Yang, K.; Abel, L.; Picard, C.; Puel, A.; Casanova, J.L. Human Toll-like receptor-dependent induction of interferons in protective immunity to viruses. Immunol. Rev. 2007, 225-236.
19. Thomson, S.J.; Goh, F.G.; Banks, H.; Krausgruber, T.; Kotenko, S.V.; Foxwell, B.M.; Udalova, I.A. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 11564-11569.
20. Osterlund, P.I.; Pietila, T.E.; Veckman, V.; Kotenko, S.V.; Julkunen, I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J. Immunol. 2007, 179, 3434-3442.
21. Ank, N.; West, H.; Bartholdy, C.; Eriksson, K.; Thomsen, A.R.; Paludan, S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral ctivity against select virus infections in vivo. J. Virol. 2006, 80, 4501-4509.
22. Siren, J.; Pirhonen, J.; Julkunen, I.; Matikainen, S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J. Immunol. 2005, 174, 1932-1937.
23. Foy, E.; Li, K.; Wang, C.; Sumpter, R., Jr.; Ikeda, M.; Lemon, S.M.; Gale, M., Jr. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003, 300, 1145-1148.
24. Foy, E.; Li, K.; Sumpter, R., Jr.; Loo, Y.M.; Johnson, C.L.; Wang, C.; Fish, P.M.; Yoneyama, M.; Fujita, T.; Lemon, S.M.; Gale, M., Jr. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 2986-2991.
25. Li, K.; Foy, E.; Ferreon, J.C.; Nakamura, M.; Ferreon, A.C.; Ikeda, M.; Ray, S.C.; Gale, M., Jr.; Lemon, S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 2992-2997.
26. Kaukinen, P.; Sillanpaa, M.; Kotenko, S.; Lin, R.; Hiscott, J.; Melen, K.; Julkunen, I. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol. J. 2006, 3, 66.
27. Zhang, T.; Lin, R.T.; Li, Y.; Douglas, S.D.; Maxcey, C.; Ho, C.; Lai, J. P.; Wang, Y.J.; Wan, Q.; Ho, W.Z. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. Hepatology 2005, 42, 819-827.
28. Mihm, S.; Frese, M.; Meier, V.; Wietzke-Braun, P.; Scharf, J.G.; Bartenschlager, R.; Ramadori, G. Interferon type I gene expression in chronic hepatitis C. Lab. Invest. 2004, 84, 1148-1159.
29. Dumoutier, L.; Tounsi, A.; Michiels, T.; Sommereyns, C.; Kotenko, S.V.; Renauld, J.C. Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-lambda1: Similarities with Type I Interferon Signaling. J. Biol. Chem. 2004, 279, 32269-32274.
30. Marcello, T.; Grakoui, A.; Barba-Spaeth, G.; Machlin, E.S.; Kotenko, S.V.; MacDonald, M. R.; Rice, C. M. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006, 131, 1887-1898.
31. Doyle, S.E.; Schreckhise, H.; Khuu-Duong, K.; Henderson, K.; Rosler, R.; Storey, H.; Yao, L.; Liu, H.; Barahmand-pour, F.; Sivakumar, P.; Chan, C.; Birks, C.; Foster, D.; Clegg, C. H.; Wietzke-Braun, P.; Mihm, S.; Klucher, K.M. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006, 44, 896-906.
32. Lasfar, A.; Lewis-Antes, A.; Smirnov, S.V.; Anantha, S.; Abushahba, W.; Tian, B.; Reuhl, K.; Dickensheets, H.; Sheikh, F.; Donnelly, R.P.; Raveche, E.; Kotenko, S. V. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 2006, 66, 4468-4477.
33. Meager, A.; Visvalingam, K.; Dilger, P.; Bryan, D.; Wadhwa, M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005, 31, 109-118.
34. Zitzmann, K.; Brand, S.; Baehs, S.; Goke, B.; Meinecke, J.; Spottl, G.; Meyer, H.; Auernhammer, C.J. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 2006, 344, 1334-1341.
35. Stark, G.R.; Kerr, I.M.; Williams, B.R.; Silverman, R.H.; Schreiber, R.D. How cells respond to interferons. Annu. Rev. Biochem. 1998, 67, 227-264.
36. Brand, S.; Zitzmann, K.; Dambacher, J.; Beigel, F.; Olszak, T.; Vlotides, G.; Eichhorst, S.T.; Goke, B.; Diepolder, H.; Auernhammer, C.J. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem. Biophys. Res. Commun. 2005, 331, 543-548.
37. Maher, S.G.; Sheikh, F.; Scarzello, A.J.; Romero-Weaver, A.L.; Baker, D.P.; Donnelly, R.P.; Gamero, A.M. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 2008, 7, 1109-1115.
38. Zhou, Z.; Hamming, O.J.; Ank, N.; Paludan, S.R.; Nielsen, A.L.; Hartmann, R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 2007, 81, 7749-7758.
39. Pagliaccetti, N.E.; Eduardo, R.; Kleinstein, S.H.; Mu, X.J.; Bandi, P.; Robek, M.D. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem. 2008, 283, 30079-30089.
40. Brand, S.; Beigel, F.; Olszak, T.; Zitzmann, K.; Eichhorst, S.T.; Otte, J.M.; Diebold, J.; Diepolder, H.; Adler, B.; Auernhammer, C.J.; Goke, B.; Dambacher, J. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289, G960-968.
41. Mukaida, N.; Harada, A.; Matsushima, K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998, 9, 9-23.
42. Yang, K.; Puel, A.; Zhang, S.; Eidenschenk, C.; Ku, C. L.; Casrouge, A.; Picard, C.; von Bernuth, H.; Senechal, B.; Plancoulaine, S.; Al-Hajjar, S.; Al-Ghonaium, A.; Marodi, L.; Davidson, D.; Speert, D.; Roifman, C.; Garty, B. Z.; Ozinsky, A.; Barrat, F.J.; Coffman, R.L.; Miller, R.L.; Li, X.; Lebon, P.; Rodriguez-Gallego, C.; Chapel, H.; Geissmann, F.; Jouanguy, E.; Casanova, J.L. Human TLR-7-, -8-, and -9-mediated induction of IFN-alpha/beta and -lambda Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 2005, 23, 465-478.
43. Zhu, H.; Butera, M.; Nelson, D.R.; Liu, C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol. J. 2005, 2, 80.
44. Hou, W.; Wang, X.; Ye, L.; Zhou, L.; Yang, Z.Q.; Riedel, E.; Ho, W.Z. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J. Virol. 2009, 83, 3834-3842.
45. Robek, M.D.; Boyd, B.S.; Chisari, F.V. Lambda Interferon Inhibits Hepatitis B and C Virus Replication. J. Virol. 2005, 79, 3851-3854.
46. Pagliaccetti, N.E.; Chu, E.N.; Bolen, C.R.; Kleinstein, S.H.; Robek, M.D. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010, 401, 197-206.
47. Almeida, G.M.; de Oliveira, D.B.; Magalhaes, C.L.; Bonjardim, C.A.; Ferreira, P.C.; Kroon, E. G. Antiviral activity of type I interferons and interleukins 29 and 28a (type III interferons) against Apeu virus. Antiviral Res. 2008, 80, 302-308.
48. Hong, S.H.; Cho, O.; Kim, K.; Shin, H.J.; Kotenko, S.V.; Park, S. Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells. Virus Res. 2007, 126, 245-249.
49. Ma, D.; Jiang, D.; Qing, M.; Weidner, J.M.; Qu, X.; Guo, H.; Chang, J.; Gu, B.; Shi, P.Y.; Block, T.M.; Guo, J.T. Antiviral effect of interferon lambda against West Nile virus. Antiviral Res. 2009, 83, 53-60.
50. Stoltz, M.; Ahlm, C.; Lundkvist, A.; Klingstrom, J. Lambda Interferon (IFN-λ) in Serum Is Decreased in Hantavirus-Infected Patients, and In Vitro-Established Infection Is Insensitive to Treatment with All IFNs and Inhibits IFN-γ-Induced Nitric Oxide Production. J. Virol. 2007, 81, 8685-8691.
51. Baize, S.; Pannetier, D.; Faure, C.; Marianneau, P.; Marendat, I.; Georges-Courbot, M.C.; Deubel, V. Role of interferons in the control of Lassa virus replication in human dendritic cells and macrophages. Microbes Infect. 2006, 8, 1194-1202.
52. Bartlett, N.W.; Buttigieg, K.; Kotenko, S.V.; Smith, G.L. Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J. Gen. Virol. 2005, 86, 1589-1596.
53. Bandi, P.; Pagliaccetti, N.E.; Robek, M.D. Inhibition of type III interferon activity by orthopoxvirus immunomodulatory proteins. J. Interferon Cytokine Res. 2010, 30, 123-34.
54. Megjugorac, N.J.; Gallagher, G.E.; Gallagher, G. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J. Leuko. Biol. 2009, 86, 1359-1363.
55. Mennechet, F.J.; Uze, G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107, 4417-4423.
56. Wolk, K.; Witte, K.; Witte, E.; Proesch, S.; Schulze-Tanzil, G.; Nasilowska, K.; Thilo, J.; Asadullah, K.; Sterry, W.; Volk, H. D.; Sabat, R. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J. Leukocyte Biol. 2008, 83, 1181-1193.
57. Jordan, W.J.; Eskdale, J.; Srinivas, S.; Pekarek, V.; Kelner, D.; Rodia, M.; Gallagher, G. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun. 2007, 8, 254-261.
58. Dai, J.; Megjugorac, N.J.; Gallagher, G.E.; Yu, R.Y.; Gallagher, G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009, 113, 5829-5838.
59. Srinivas, S.; Dai, J.; Eskdale, J.; Gallagher, G.E.; Megjugorac, N.J.; Gallagher, G. Interferonlambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008, 125, 492-502.
60. Jordan, W.J.; Eskdale, J.; Boniotto, M.; Rodia, M.; Kellner, D.; Gallagher, G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8, 13-20.
61. Pekarek, V.; Srinivas, S.; Eskdale, J.; Gallagher, G. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an FNgamma- dependent manner. Genes Immun. 2007, 8, 177-180.
62. Rauch, A.; Kutalik, Z.; Descombes, P.; Cai, T.; di Iulio, J.; Mueller, T.; Bochud, M.; Battegay, M.; Bernasconi, E.; Borovicka, J.; Colombo, S.; Cerny, A.; Dufour, J.F.; Furrer, H.; Gunthard, H.F.; Heim, M.; Hirschel, B.; Malinverni, R.; Moradpour, D.; Mullhaupt, B.; Witteck, A.; Beckmann, J.S.; Berg, T.; Bergmann, S.; Negro, F.; Telenti, A.; Bochud, P.Y. Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study. Gastroenterology 2009, 138, 1338-1345.
63. Suppiah, V.; Moldovan, M.; Ahlenstiel, G.; Berg, T.; Weltman, M.; Abate, M.L.; Bassendine, M.; Spengler, U.; Dore, G.J.; Powell, E.; Riordan, S.; Sheridan, D.; Smedile, A.; Fragomeli, V.; Muller, T.; Bahlo, M.; Stewart, G.J.; Booth, D.R.; George, J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41, 1100-1104.
64. Tanaka, Y.; Nishida, N.; Sugiyama, M.; Kurosaki, M.; Matsuura, K.; Sakamoto, N.; Nakagawa, M.; Korenaga, M.; Hino, K.; Hige, S.; Ito, Y.; Mita, E.; Tanaka, E.; Mochida, S.; Murawaki, Y.; Honda, M.; Sakai, A.; Hiasa, Y.; Nishiguchi, S.; Koike, A.; Sakaida, I.; Imamura, M.; Ito, K.; Yano, K.; Masaki, N.; Sugauchi, F.; Izumi, N.; Tokunaga, K.; Mizokami, M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41, 1105-1109.
65. Thomas, D.L.; Thio, C.L.; Martin, M. P.; Qi, Y.; Ge, D.; O'Huigin, C.; Kidd, J.; Kidd, K.; Khakoo, S.I.; Alexander, G.; Goedert, J.J.; Kirk, G.D.; Donfield, S. M.; Rosen, H.R.; Tobler, L.H.; Busch, M.P.; McHutchison, J.G.; Goldstein, D.B.; Carrington, M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461, 798-801.
66. Ge, D.; Fellay, J.; Thompson, A.J.; Simon, J.S.; Shianna, K.V.; Urban, T.J.; Heinzen, E.L.; Qiu, P.; Bertelsen, A.H.; Muir, A.J.; Sulkowski, M.; McHutchison, J.G.; Goldstein, D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461, 399-401.
67. Thompson, A.J.; Muir, A.J.; Sulkowski, M.S.; Ge, D.; Fellay, J.; Shianna, K.V.; Urban, T.; Afdhal, N.H.; Jacobson, I.M.; Esteban, R.; Poordad, F.; Lawitz, E.J.; McCone, J.; Shiffman, M. L.; Galler, G.W.; Lee, W.M.; Reindollar, R.; King, J.W.; Kwo, P.Y.; Ghalib, R.H.; Freilich, B.; Nyberg, L.M.; Zeuzem, S.; Poynard, T.; Vock, D.M.; Pieper, K.S.; Patel, K.; Tillmann, H.L.; Noviello, S.; Koury, K.; Pedicone, L.D.; Brass, C.A.; Albrecht, J.K.; Goldstein, D.B.; McHutchison, J.G. IL28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitic C virus. Gastroenterology 2010, 139, 120-129.
68. Conjeevaram, H.S.; Fried, M.W.; Jeffers, L.J.; Terrault, N.A.; Wiley-Lucas, T.E.; Afdhal, N.; Brown, R.S.; Belle, S.H.; Hoofnagle, J.H.; Kleiner, D.E.; Howell, C.D. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131, 470-477.
69. Sarasin-Filipowicz, M.; Oakeley, E.J.; Duong, F.H.; Christen, V.; Terracciano, L.; Filipowicz, W.; Heim, M.H. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 7034-7039.
70. He, X.S.; Ji, X.; Hale, M.B.; Cheung, R.; Ahmed, A.; Guo, Y.; Nolan, G.P.; Pfeffer, L.M.; Wright, T. L.; Risch, N.; Tibshirani, R.; Greenberg, H. B. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006, 44, 352-359.
71. Miller, D.M.; Klucher, K.M.; Freeman, J.A.; Hausman, D.F.; Fontana, D.; Williams, D.E. Interferon lambda as a potential new therapeutic for hepatitis C. Ann. N.Y. Acad. Sci. 2009, 1182, 80-87.
72. Muir, A.J.; Shiffman, M.L.; Zaman, A.; Yoffe, B.; de la Torre, A.; Flamm, S.; Gordon, S.C.; Marotta, P.; Vierling, J.M.; Carlos Lopez-Talavera, J.; Byrnes-Blake, K.; Fontana, D.; Freeman, J.; Gray, T.; Hausman, D.; Hunder, N.N.; Lawitz, E. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010, doi: 10.1002/hep.23743.
73. Fried, M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36, S237-S244.